Blinatumomab or inotuzumab ozogamicin as bridge to allogeneic stem cell transplantation in relapsed or refractory B-lineage acute lymphoblastic leukemia: a retrospective single center analysis
Here, we report the clinical course of 34 adult patients receiving Blinatumomab or Inotuzumab ozogamicin for relapsed or refractory acute lymphoblastic leukaemia. Both agents induced high rates of (molecular) complete remissions and showed manageable toxicity profiles, allowing 80% of transplantable patients to proceed to allo-SZT. These data suggest a high efficacy and safety of both drugs in a bridge-to-transplant setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Patrick Stelmach, Klaus Wethmar, Christoph Groth, Daniela V. Wenge, J örn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants